FGEN

FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote

Why FibroGen's Stock Is Getting Hammered Today

FibroGen Staring At Multi-Year Lows Following Adverse Roxadustat AdCom Verdict; How Hard Will The Stock Likely Fall?

FibroGen Stock Craters After Roxadustat Setback, But There Is A Silver Lining

FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease

What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict